BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes

  Esperion announced positive top-line results from the Phase 2 bempedoic acid / ezetimibe combination tablet study.

  August 30, 2019

   · 

  10 min read
• Drug Development

  Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress

  Akari Therapeutics, Plc announced financial results for the second quarter ended June 30, 2019 and recent clinical progress.

  August 30, 2019

   · 

  10 min read
• Bittium Exhibits Its Cardiac Monitoring Products and Solutions at ESC Congress 2019

  Bittium Exhibits Its Cardiac Monitoring Products and Solutions at ESC Congress 2019

  August 30, 2019

   · 

  3 min read
• 

  New Research Could Help Personalize Treatment for Myasthenia Gravis

  Researchers with the University of Alberta recently identified a unique biological marker for myasthenia gravis that might be used for a diagnostic test and to predict the course of the disease. It may also have implications for defining more personalized treatments.

  August 30, 2019

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  AbbVie Out $5.8 Billion After Scrapping Rova-T Program

  AbbVie announced that the Phase III MERU trial evaluating Rova-T as first-line maintenance therapy for advanced small-cell lung cancer, failed to demonstrate a survival benefit following a pre-planned interim analysis.

  August 30, 2019

   · 

  2 min read

   · 

  Alex Keown
• Business

  Pneumagen Appoints Scientific Advisory Board

  Pneumagen Ltd announced appointments to its Scientific Advisory Board, bringing international expertise in the areas of respiratory disease, immunology and oncology.

  August 30, 2019

   · 

  2 min read
• Business

  Promore Pharma AB (publ) Interim report January - June 2019

  The first half of the year has been characterized by continued work to develop the company’s innovative projects in two treatment areas, both of which have significant medical needs because the current treatment options are less effective or non-existent.

  August 30, 2019

   · 

  4 min read
• 

  Business

  Anthony Grosso appointed Head of Scientific Affairs at Accord Healthcare Europe

  Anthony Grosso has been appointed to the role of Head of Scientific Affairs [SA] at Accord Healthcare Europe.

  August 30, 2019

   · 

  2 min read
• 

  Business

  Adrenomed Supervisory Board appoints Jens Schneider-Mergener as CEO and Jens Zimmermann, CMO, joins the Executive Board

  Adrenomed AG, the vascular integrity company, announced that its Supervisory Board has appointed two new members of the Executive Board.

  August 30, 2019

   · 

  4 min read
• 

  Job Trends

  Neos Therapeutics to Present at Two Upcoming September 2019 Conferences

  Neos Therapeutics, Inc. announced that Jerry McLaughlin, Chief Executive Officer, will present a company overview at two upcoming conferences in September

  August 30, 2019

   · 

  1 min read